Rising awareness of animal welfare has emerged as a significant driver for the market.
As pet owners increasingly recognize the importance of postoperative care, they are more likely to seek veterinary treatments and medications to manage their pets’ pain after surgical procedures. This trend is further amplified by the growing emphasis on animal welfare and the ethical treatment of pets, which is supported by various government regulations and guidelines.
Moreover, the trend of pet humanization, where pets are treated as family members, has further amplified the importance of compassionate care. Pet owners are more inclined to invest in advanced postoperative pain management therapies, including pharmaceuticals and alternative treatments, to provide the best possible care for their pets. This shift in mindset has resulted in an increased willingness to pay for premium postoperative pain management drugs that offer enhanced efficacy and safety.
Additionally, the role of veterinarians and animal welfare organizations in educating pet owners about the importance of pain management has been crucial. These professionals emphasize the ethical responsibility of minimizing animal suffering, which has led to a greater adoption of pain management practices.
As a result, rising awareness of animal welfare, coupled with the humanization of pets and the influence of veterinary guidance, has significantly contributed to the growth of the market.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
Global companion animal postoperative pain management therapeutics industry was valued at USD 133.5 million in 2023 and is anticipated to register 6.5% CAGR between 2024 and 2032, driven by the increasing prevalence of surgical procedures in companion animals.
The oral segment in the market accounted 57.1% revenue share in 2023 due to its convenience, ease of administration, and effective pain relief.
U.S. companion animal postoperative pain management therapeutics market accounted USD 59.2 million in 2023, driven by a combination of advanced veterinary care infrastructure and high pet ownership rates.
Assisi Animal Health, Bayer AG, Bimeda Animal Health, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Chanelle Pharma Group, Dechra Pharmaceuticals, Elanco Animal Health Incorporated, and Merck Animal Health, among others.